A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

Atherosclerosis
Juan GaztanagaZahi A Fayad

Abstract

Arachidonate 5-lipoxygenase (5-LO) is a key enzyme in the synthesis of leukotrienes. VIA-2291 is a potent 5-LO inhibitor, which has been shown to reduce hsCRP and noncalcified coronary plaque volume following an acute coronary syndrome (ACS). We aim to evaluate the effect of VIA-2291 on vascular inflammation compared to placebo using FDG-PET. A Phase II, randomized, double-blind, parallel-group study was conducted in 52 patients with recent ACS assigned 1:1 to either 100 mg VIA-2291 or placebo for 24 weeks. The primary outcome was the effect of VIA-2291 relative to placebo on arterial inflammation detected by (18)fluorodeoxyglucose positron emission tomography (FDG-PET) within the index vessel after 24 weeks of daily treatment, compared to baseline. VIA-2291 was relatively well tolerated and was associated with a significant inhibition of the potent chemo-attractant LTB4, with a mean inhibition of activity of 92.8% (p<0.0001) at 6 weeks in the VIA-2291 group, without further significant change in inhibition at 24 weeks. However, for VIA-2291 was not associated with significant difference in inflammation (target-to-background ratio) compared to placebo at 24 weeks or 6 weeks of treatment. Further, VIA-2291 was not associated wit...Continue Reading

References

Aug 18, 1994·The New England Journal of Medicine·G LiuzzoA Maseri
Jun 22, 1999·The New England Journal of Medicine·G D Sloop
Sep 28, 2000·The New England Journal of Medicine·J A GoldsteinW W O'Neill
Jul 5, 2002·The New England Journal of Medicine·Antonino BuffonAttilio Maseri
Nov 13, 2002·Journal of the American College of Cardiology·Luigi Giusto SpagnoliFilippo Crea
Sep 17, 2003·Circulation·Scott KinlayUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Mar 31, 2004·The American Journal of Medicine·Peter Libby, Paul M Ridker
Jun 3, 2004·Circulation·David P FaxonUNKNOWN American Heart Association
Jul 29, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jaime LlodráGwendalyn J Randolph
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen
Mar 15, 2008·Respiratory Medicine·Juan J TelleriaIgnacio Diez
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Mar 2, 2010·Circulation. Cardiovascular Imaging·Jean-Claude TardifJosephine Pressacco
Nov 24, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Yen-Wen WuWei-Shiung Yang

❮ Previous
Next ❯

Citations

Jan 30, 2016·Future Medicinal Chemistry·Simon B M KretschmerBettina Hofmann
Dec 19, 2015·European Journal of Nuclear Medicine and Molecular Imaging·Jan BuceriusUNKNOWN Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)
May 26, 2015·Bioorganic & Medicinal Chemistry Letters·Daniel PettersenCarl Whatling
Nov 27, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Cong-Lin LiuGuo-Ping Shi
Oct 26, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Arshag D Mooradian
Dec 9, 2016·Expert Opinion on Emerging Drugs·Marie-Jeanne Bertrand, Jean-Claude Tardif
Dec 23, 2016·Expert Opinion on Therapeutic Patents·Oliver WerzUlrike Garscha
May 26, 2018·Future Science OA·Alastair J MossMarc R Dweck
Aug 16, 2018·The Journal of Clinical Investigation·Canan KasikaraIra Tabas
Jun 27, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Fabien Hyafil, Jonathan Vigne
Dec 24, 2019·Expert Opinion on Investigational Drugs·Amit RoutPaul A Gurbel
Apr 23, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Julie ButtersStephen J Nicholls
Sep 4, 2020·Current Atherosclerosis Reports·Oluremi N Ajala, Brendan M Everett
Mar 25, 2021·Immunotherapy·Konstantinos S MylonasDimitrios Schizas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.